PHP20 Real-World Utilization Pattern of Biologics in Rheumatoid Arthritis: A Population-Based Study  by Liao, C.H. et al.
PHP20
REAL-WORLD UTILIZATION PATTERN OF BIOLOGICS IN RHEUMATOID
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Liao CH, Wang YC, Chen JJ, Pwu RF
Center for Drug Evaluation, Taipei, Taiwan
OBJECTIVES: In November 2011, Center for Drug Evaluation completed the project
which aimed to re-evaluate the currently reimbursed biologics for rheumatoid
arthritis (RA), and to establish the evidence-based revision rules of reimbursed
items covered by National Health Insurance (NHI). As part of the project, this study
analyzed the NHI claim data to capture the utilization and prescription pattern of
reimbursed biologics in adult patients.METHODS: Identity-encrypted claims data,
including inpatient, ambulatory care and contracted pharmacies prescriptions,
during 2001 to 2010 were utilized. All records with etanercept, adalimumab and
rituximabwere identified in the first step. Then the records were further separated
into RA and non-RA usage, according to the diagnosis codes. Moreover, the RA
patients who were newly treated with biologics were enrolled to assess long-term
prescription pattern.We performed both Kaplan-Meier analyses to assess biologics
switching over time and medication possession rates to evaluate medication
compliance. RESULTS: The expenditure of biologics for RA patients increased rap-
idly in the past decade and came to NT$ 1.37 billion in 2010. Among 5,142 patients
treated by biologics in 2010, 88% received etanercept or adalimumab, and 12%
received rituximab. In prescription pattern analysis, rituximab was not reported
due to lack of long-term data (reimbursed for RA since November 2008). A total of
3,928 and 1,508 patients initialed by etanercept and adalimumab were analyzed,
separately. About 34% of etanercept subjects appeared switching over 85 months
and 27% of adalimumab subjects applied second biologics over 45 months. The
mean durations of continuous prescription were 29 months and 14 months, and
the medication possession rates were 78% and 93%, respectively. CONCLUSIONS:
Under current reimbursement rules, the persistence and compliance of biologic for
RA patients were satisfactory. However, the increasing numbers of patients and
biological alternatives might intensify the financial pressure on NHI.
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DOES NATIONAL ESSENTIAL MEDICINE SYSTEM IMPROVE RATIONAL DRUG
USE IN PRIMARY HEALTH CARE FACILITIES? AN EMPIRICAL STUDY IN RURAL
CHINA
Song Y, Bian Y
University of Macau, Macau, Macau, China
OBJECTIVES: To examine the effect of National Essential Medicine System (NEMS)
on rational drug use (RDU) in primary health care facilities in rural China and to
provide reflections and policy implications for currently implemented new health
care reform. METHODS: Data was obtained from 151 township hospitals in four
provinces by means of field survey (stratified random sampling) conducted be-
tween 20102011. Indicators of RDU were compared before and after NEMS, and
discussed in regard to WHO Standard Guidelines or data from other researches.
RESULTS: Under NEMS, average number of drugs per encounter decreased from
3.64 to 3.46 (p0.01). Little effectwas found in the average number of antibiotics per
encounter, but the percentage of encounters with antibiotics prescribed decreased
from 60.26% to 58.48%(p0.01). The percentage of encounters with injection pre-
scribed and the percentage of encounters with hormone prescribed also decreased
and the current proportion was 40.31% and 11.16%, respectively. But unfortunately
all the above values remained higher than WHO international standards. The per-
centage of drugs prescribed from National Essential Drug List increased from
63.33% to 79.89% (p0.01). The average expenses per encounter increased from
RMB 25.77 to 26.71 with the available data, but was not significant (p0.362) and
warranted further investigation.CONCLUSIONS:The implementation of NEMShas
greatly improved rational drug use in primary health care facilities in rural China.
But the over-prescription of antibiotics and injections and polypharmacy remain
common. Treatment guidelines should be established and closely adhered to. Con-
tinuingmedical education on RDU for both healthworkers and the public aswell as
intensive support supervision are the essential actions taken.
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DRUGS-KETOROLAC IN A NATIONALLY REPRESENTATIVE POPULATION
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OBJECTIVES: Emerged evidence has linked non-steroidal anti-inflammatory drugs
(NSAIDs) to cardiovascular adverse outcomes. Specifically, parenteral NSAIDs such
as ketorolac were associated with higher risk of adverse outcomes than oral ones.
Recent policy concern has therefore focused on the rational use of parenteral
NSAIDs. Using 2000-2009 Taiwan’s National Health Insurance research database
(NHIRD), the objective of this study was to provide an estimate of off-label use of
ketorolac in a nationally representative sample.METHODS: Inpatient (n303,733)
and outpatient prescriptions (n605,750) of parenteral ketorolac from 2000
through 2009 were identified from a random sample of 1,000,000 individuals in
NHIRD in 2005. Ketorolac prescribing outside the indications approved by the Tai-
wan Food and Drug Administration (i.e. short term use ( 5 days) for postoperative
pain) was defined as off-label use. Differences in patient and prescriber character-
istics between licensed and off-label prescriptions were assessed with chi-square
tests for categorical variables and t-tests for continuous variables. RESULTS: Off-
label use of ketorolac was estimated to be 28.5% at the inpatient settings. The
off-label use was more frequent at the outpatient settings (90% of the outpatient
prescriptions), with the highest proportion of off-label use among pediatric pa-
tients (6 years old (y/o): 97.2%, 6-18 y/o: 95.8%, 18-65 y/o: 95.1%, and 65 y/o:
94.7%). Approximately 50% of the outpatient off-label prescriptions of ketorolac
came from metropolitan hospitals. Also, the majority of the outpatient off-label
prescriptions of ketorolac were prescribed by the emergency departments.
CONCLUSIONS: Our results suggest that the actual extent of off-label use of ke-
torolac could be very high, especially at the outpatient settings. It highlights the
need for a better understanding of the reasons behind this phenomenon, a more
appropriate definition of the role of ketorolac in pain managements, and a more
efficient policy intervention to rationalize the use of ketorolac.
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DOES COMBINATION PHARMACOLOGICAL INTERVENTION FOR SMOKING
CESSATION PREVENT POST-CESSATION WEIGHT GAIN?
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OBJECTIVES: A systematic review was conducted to summarize if combination
pharmacological therapy for smoking cessation offers an effective way to reduce
post-cessation weight gain.METHODS: The following databases were researched:
Medline, Pubmed, PsycINFO, CENTRAL and EMBASE. Detailed inclusion and exclu-
sion criteria were specified a prioribefore conducting abstract and full text screen-
ing. Included studies were required to: 1) report data on combination pharmaco-
therapy including at least one FDA-approved smoking cessation medication; 2)
report outcome measure of weight change; 3) incorporate a minimum of 2-week
follow-up; and 4) recruit adult smokers. Studies were excluded if they had 1) be-
havioral interventions; 2) sample size of  30; 3) switching medications; or 4) they
were not written in English. Abstracts and the full texts were reviewed indepen-
dently by two investigators. Inclusion of studies was decided by a third indepen-
dent investigator in case of disagreement between the two primary investigators.
RESULTS:Out of 1873 citations identified, a total of 1083 citationswere included for
abstract screening. Finally 13 studies met the eligibility criteria after full text
screening of 242 citations. Seven studies showed that participants in the combined
therapy group had less post-cessation weight gain than those in the group of indi-
vidual drugs or placebo. Four studies did not report differential weight gain mea-
sures by treatment groups, another study only reported the results of F-tests
among treatment groups, and smoking cessation groups without reporting pre-
post average weight change. Only one study showed that post-treatment weight
gain in the combined therapy group was more than the monotherapy group, al-
though the result was not statistically significant. CONCLUSIONS: Seven out of
thirteen studies indicated that combination smoking cessation medications had
less post-cessation weight gain than monotherapy or placebo in short term. Long
termweight gain was not well documented bymost of the studies and is subjected
to future research.
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ASSESSMENT OF THE IN EXCESS NHI-COVERED MEDICATIONS OF
OUTPATIENTS IN A 2000-BED MEDICAL CENTER IN TAIWAN
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OBJECTIVES: To evaluate the extent of excess NHI-covered medications in China
Medical University Hospital (CMUH), as the surrogate indicator of inappropriate
prescribing andmedication practices.METHODS: Those patients who have visited
outpatient units in CMUH 3 for 50% of all outpatient visits were assigned as CMUH
loyal patients by Bureau of NHI in Taiwan. They have received Integrated Medical
Care (IMC) services in CMUH since December 2009. Patients who have visited out-
patient units in CMUH, including those in IMC services, were encouraged to recycle
their excess prescription medications to the Department of Pharmacy and learn
about proper medication use and its disposal during July 2011 to February 2012.
Those retrieved prescription medications were classified based upon their clinical
applications and checked for their reimbursed cost using information obtained
from the Bureau of NHI. The differences during implementation period between
IMC service group and usual care (UC) group were compared using Chi-squaredtest
and t-tests. RESULTS: While 32 patients in IMC group and 15 in the UC group
recycled their excess medications, more patients in the IMC group had coronary
artery disease (p0.03). Although IMC group have made more outpatient visits
significantly thanUCgroup (2924 vs. 99, p 0.004), their inpatient visits in CMUH
were similar. The average pill counts were 433119 versus 22360 (p 0.03) and
cost of excess prescription medication were 2,219607 versus 2,126950 NTD in
IMC andUC group, respectively.While HTN, DMandhyperlipidemiawere the three
major diseases in both groups, those agents for cardiovascular disease and DM
accounted for 39% and 15% of all estimated cost of excess medication.
CONCLUSIONS:With the substantial excess, NHI-covered medications for chronic
illness among CMUH outpatients, it is necessary to come up with workable strat-
egies to enhance appropriate prescribing and medication use in outpatient units.
PHP25
MARKET ANALYSIS OF ANTIBIOTICS CONSUMPTION IN NORTHERN PART OF
IRAN DURING 2001-2010
Zaboli P1, Ala S2, Kebriaee Zadeh A1, Abdollahiasl A3, Nikfar S1
1Tehran University of Medical Sciences, Tehran, Tehran, Iran, 2Mazandaran University of
Medical Sciences, Sari, Mazandaran, Iran, 3Tehran University of Medical Sciences, Tehran, Iran
OBJECTIVES: Iran’s Rational Drug Use Committee (RUD) reported that antibiotics’
consumption rate has been arisen in the past decade and theywere among the first
five most used drugs. Irrational use of antibiotics can cause microbial resistance
and move a huge part of the government financial support, this research looks
forward to study about the antibiotic consumption’s in Northern stateswhich have
around 10% of the whole Iran’s population and comparing them with Iran’s total
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